Medrx - Japan Biotech Microcap in Potential Big Licensing Deal
Although the Japanese drug industry suffers from a lack of scale, where it is good is in applying manufacturing techniques to develop not just...
427 Views
PeptiDream: J&J Latest Drug Major to Tie Up
On the surface, Peptidream's (4587 JP) deal with Johnson & Johnson's (JNJ US) Janssen unit looks no different from the deals they have cut with...
340 Views
Sosei & Kyowa Hakko Kirin: Positive News on GPCR Drugs
Kyowa Hakko Kirin's (4151 JP) announcement that “moga” – mogamulizumab (KW-0761) – has met its primary endpoint (PFS) in Phase III trials for...
284 Views
Death Rattle for Defensives?
While it is not a given that a switch from a high growth, high interest rate environment to a low growth, low interest rate environment is a good...
1k Views
Opdivo Singled Out in Government Rule Change
The suggestion of government orchestration against Ono’s immunotherapy treatment Opdivo (nivolumab) has moved a stage further with a report in the...
5.7k Views